{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:49:06Z","timestamp":1793774946148,"version":"4.6.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CERTAINTY"],"award-info":[{"award-number":["CERTAINTY"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02933-2","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:59:46Z","timestamp":1774965586000},"page":"872-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of CAR T cells in multiple myeloma \u2013 the good, the bad, and the ugly"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jurgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fandrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":false,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2933_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall AL, Maus MV, Hwang W-T, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040\u20131047.","journal-title":"N Engl J Med"},{"key":"2933_CR2","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u20131700.","journal-title":"Blood"},{"key":"2933_CR3","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol J Am Soc Clin Oncol. 2018;36:2267\u20132280.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2933_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u2013554.","journal-title":"Leukemia"},{"key":"2933_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u2013716.","journal-title":"N Engl J Med"},{"key":"2933_CR6","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29:2286\u20132294.","journal-title":"Nat Med"},{"key":"2933_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u20131014.","journal-title":"N Engl J Med"},{"key":"2933_CR8","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144:2389\u20132401.","journal-title":"Blood"},{"key":"2933_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet Lond Engl. 2021;398:314\u2013324.","journal-title":"Lancet Lond Engl"},{"key":"2933_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol J Am Soc Clin Oncol. 2023;41:1265\u20131274.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2933_CR11","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol J Am Soc Clin Oncol. 2025;43:2766\u20132771.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2933_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u2013347.","journal-title":"N Engl J Med"},{"key":"2933_CR13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol J Am Soc Clin Oncol. 2024;42:1665\u20131675.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2933_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici A-M, von Tresckow B, Rathje K, Fenk R, Holderried T, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. HemaSphere. 2025;9:e70070.","journal-title":"HemaSphere"},{"key":"2933_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2025028330","volume":"146","author":"M Merz","year":"2025","unstructured":"Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, et al. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood. 2025;146:1677\u20131686.","journal-title":"Blood"},{"key":"2933_CR16","doi-asserted-by":"crossref","unstructured":"Rade M, Fandrei D, Kreuz M, Seiffert S, Grahnert A, Friedrich M, et al. A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. Cancer Cell. 2025;44:586\u2013603.","DOI":"10.1016\/j.ccell.2025.10.014"},{"key":"2933_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol J Am Soc Clin Oncol. 2025;43:1597\u20131609.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2933_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Mor\u00e1n-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:180.","journal-title":"Blood Cancer J"},{"key":"2933_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01320-x","volume":"15","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, Hosoya H, Mikkilineni L, Hansen DK, Wolf JL, Lin Y. Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma. Blood Cancer J. 2025;15:112.","journal-title":"Blood Cancer J"},{"key":"2933_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"2933_CR21","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of Parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u20132103.","journal-title":"Nat Med"},{"key":"2933_CR22","first-page":"71.e1","volume":"31","author":"Ellithi","year":"2025","unstructured":"Ellithi, Elsallab M, Lunning MA M, Holstein SA, Sharma S, Trinh JQ, et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transpl Cell Ther. 2025;31:71.e1\u201371.e14.","journal-title":"Transpl Cell Ther"},{"key":"2933_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01384-9","volume":"15","author":"M Korenkov","year":"2025","unstructured":"Korenkov M, Liebaert J, Yousefian S, Schwartz S, Demel UM, Braune J, et al. Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy. Blood Cancer J. 2025;15:168.","journal-title":"Blood Cancer J"},{"key":"2933_CR24","doi-asserted-by":"crossref","unstructured":"Irfan S, Ayoobkhan FS, Vojjala N, Qureshi R, Rahman R, Kamboj, I et al. Immune effector cell-associated HLH-like syndrome (IEC-HS) in CAR-T and TCE-treated myeloma and B-cell malignancies: insights from a pharmacovigilance study. Transplant Cell Ther. 2025;32:292.","DOI":"10.1016\/j.jtct.2025.12.947"},{"key":"2933_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","volume":"39","author":"T Braun","year":"2025","unstructured":"Braun T, Kuschel F, Reiche K, Merz M, Herling M. Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia. 2025;39:1337\u20131341.","journal-title":"Leukemia"},{"key":"2933_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392:577\u2013583.","journal-title":"N Engl J Med"},{"key":"2933_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","volume":"31","author":"T Braun","year":"2025","unstructured":"Braun T, Rade M, Merz M, Klepzig H, Gro\u00dfe F, Fandrei D, et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat Med. 2025;31:1145\u20131153.","journal-title":"Nat Med"},{"key":"2933_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al. CAR+ T-cell lymphoma after Cilta-cel therapy for relapsed or refractory myeloma. N Engl J Med. 2025;392:677\u2013685.","journal-title":"N Engl J Med"},{"key":"2933_CR29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","volume":"31","author":"R Dulery","year":"2025","unstructured":"Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, et al. T cell malignancies after CAR Tcell therapy in the DESCAR-T registry. Nat Med. 2025;31:1130\u20131133.","journal-title":"Nat Med"},{"key":"2933_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01319-4","volume":"15","author":"K Somay","year":"2025","unstructured":"Somay K, Azakli H, Chahine JJ, Loughney TM, Ozdemirli M. Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder? Blood Cancer J. 2025;15:117.","journal-title":"Blood Cancer J"},{"key":"2933_CR31","first-page":"438.e1","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther Publ Am Soc Transpl Cell Ther. 2023;29:438.e1\u2013438.e16.","journal-title":"Transpl Cell Ther Publ Am Soc Transpl Cell Ther"},{"key":"2933_CR32","doi-asserted-by":"crossref","unstructured":"Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A, et al. Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities following ciltacabtagene autoleucel. MedRxiv Prepr Serv Health Sci. 2025;10:28.25338924.","DOI":"10.1101\/2025.10.28.25338924"},{"key":"2933_CR33","doi-asserted-by":"publisher","first-page":"S965","DOI":"10.1016\/S2152-2650(25)02685-0","volume":"25","author":"Y Lin","year":"2025","unstructured":"Lin Y, Oca RMde, Dhakal B, Mina R, Manier S, Rodr\u00edguez-Otero P, et al. MM-1081: absolute lymphocyte count as a key biomarker for monitoring safety after ciltacabtagene autoleucel. Clin Lymphoma Myeloma Leuk. 2025;25:S965.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2933_CR34","first-page":"S234","volume":"31","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Chhabra S, Corraes ADMS, Parrondo RD, Gertz M, Hwa L, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Transpl Cell Ther. 2025;31:S234\u201335.","journal-title":"Transpl Cell Ther"},{"key":"2933_CR35","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28:1848\u201359.","journal-title":"Nat Med"},{"key":"2933_CR36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","volume":"38","author":"L Fischer","year":"2024","unstructured":"Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia. 2024;38:372\u2013382.","journal-title":"Leukemia"},{"key":"2933_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602:503\u20139.","journal-title":"Nature"},{"key":"2933_CR38","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai Z, Feng B, McClory SE, de Oliveira BC, Diorio C, Gregoire C, et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature. 2024;634:702\u201311.","journal-title":"Nature"},{"key":"2933_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","volume":"21","author":"P Neri","year":"2024","unstructured":"Neri P, Leblay N, Lee H, Gulla A, Bahlis NJ, Anderson KC. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol. 2024;21:590\u2013609.","journal-title":"Nat Rev Clin Oncol"},{"key":"2933_CR40","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood-2023-182298","volume":"142","author":"R Montes de Oca","year":"2023","unstructured":"Montes de Oca R, Gu J, Zhao H, Zelinsky K, Wu D, Davis C, et al. Biomarker correlates of response to ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma from CARTITUDE-1, a phase 1b\/2 open-label study, at the ~3 year follow-up. Blood. 2023;142:2099.","journal-title":"Blood"},{"key":"2933_CR41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/jcph.70075","volume":"65","author":"F Wu","year":"2025","unstructured":"Wu F, Zheng X, Burnett J, Masilamani M, Zhang W, Zhong X, et al. Characterizing cellular expansion of idecabtagene vicleucel and association with clinical efficacy and safety in patients with triple-class-exposed relapsed\/refractory multiple myeloma. J Clin Pharm. 2025;65:1568\u201376.","journal-title":"J Clin Pharm"},{"key":"2933_CR42","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S2152-2650(23)01612-9","volume":"23","author":"Larrea","year":"2023","unstructured":"Larrea, de CF, Harrison, Martinez-Lopez S, Mateos J, Oriol M-V, et al. OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial. Clin Lymphoma Myeloma Leuk. 2023;23:S28.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2933_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60980-2","volume":"16","author":"D Atanackovic","year":"2025","unstructured":"Atanackovic D, Luetkens T, Schneider D, Hu P, Wang X, Shetty AC, et al. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat Commun. 2025;16:6154.","journal-title":"Nat Commun"},{"key":"2933_CR44","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","volume":"5","author":"M Rade","year":"2024","unstructured":"Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat Cancer. 2024;5:1318\u201333.","journal-title":"Nat Cancer"},{"key":"2933_CR45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2025-256","volume":"146","author":"K Patel","year":"2025","unstructured":"Patel K, Dhakal B, Kaur G, Maziarz R, Callander N, Sperling A, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: Updated results from iMMagine\u20131. Blood. 2025;146:256.","journal-title":"Blood"},{"key":"2933_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1182\/blood-2025-269","volume":"146","author":"S Richard","year":"2025","unstructured":"Richard S, Gaballa M, Gregory T, Chhabra S, Anderson L, Costa L, et al. Safety and efficacy of AZD0120, a BCMA\/CD19 dual-targeting CAR T-cell therapy, in relapsed\/refractory multiple myeloma: preliminary Results from the DURGA-1 Phase 1b\/2 study. Blood. 2025;146:269.","journal-title":"Blood"},{"key":"2933_CR47","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2025-LBA-1","volume":"146","author":"S Harrison","year":"2025","unstructured":"Harrison S, Ho PJ, Lim S-L, Talam S, Pahl H, Dingar D, et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146:LBA-1.","journal-title":"Blood"},{"key":"2933_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01410-w","volume":"15","author":"P Rodr\u00edguez-Otero","year":"2025","unstructured":"Rodr\u00edguez-Otero P, Sidana S, Kouwenhoven M, Schecter JM, Lendvai N, De Braganca KC, et al. Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4. Blood Cancer J. 2025;15:209.","journal-title":"Blood Cancer J"},{"key":"2933_CR49","unstructured":"Safety & Side Effects | CARVYKTI\u00ae (ciltacabtagene autoleucel) HCP. https:\/\/www.carvyktihcp.com\/carvykti-safety\/ (accessed 18 Dec2025)."},{"key":"2933_CR50","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","volume":"8","author":"M Mejia Saldarriaga","year":"2024","unstructured":"Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024;8:3859\u201369.","journal-title":"Blood Adv"},{"key":"2933_CR51","doi-asserted-by":"crossref","unstructured":"Lim KJC, Tan M, Parrondo R, Chhabra S, Dooley K, De Menezes Silva Corraes A, et al. Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma. Blood Cancer J. 2025;16:18.","DOI":"10.1038\/s41408-025-01441-3"},{"key":"2933_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11894-016-0491-3","volume":"18","author":"M Uzzan","year":"2016","unstructured":"Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. Gastrointestinal disorders associated with common variable immune deficiency (CVID) and chronic granulomatous disease (CGD). Curr Gastroenterol Rep. 2016;18:17.","journal-title":"Curr Gastroenterol Rep"},{"key":"2933_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01119-2","volume":"14","author":"A Khurana","year":"2024","unstructured":"Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, et al. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. Blood Cancer J. 2024;14:136.","journal-title":"Blood Cancer J"},{"key":"2933_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2024.101557","volume":"37","author":"C Chabannon","year":"2024","unstructured":"Chabannon C, Ruggeri A, Montoto S, van Biezen A, van der Werf S, Markslag A, et al. Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: collection of real-world data in the context of hematopoietic cellular therapies. Best Pr Res Clin Haematol. 2024;37:101557.","journal-title":"Best Pr Res Clin Haematol"},{"key":"2933_CR55","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390:2047\u201360.","journal-title":"N Engl J Med"},{"key":"2933_CR56","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","volume":"35","author":"F Maura","year":"2021","unstructured":"Maura F, Weinhold N, Diamond B, Kazandjian D, Rasche L, Morgan G, et al. The mutagenic impact of melphalan in multiple myeloma. Leukemia. 2021;35:2145\u201350.","journal-title":"Leukemia"},{"key":"2933_CR57","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe G, Br\u00fcggemann M, Baermann B-N, Wiegand L, Trautmann H, Yousefian S, et al. Aggressive lymphoma after CD19 CAR T-cell therapy. N Engl J Med. 2024;391:1217\u201326.","journal-title":"N Engl J Med"},{"key":"2933_CR58","doi-asserted-by":"publisher","unstructured":"Aleman A, Oekelen OV, Melnekoff DT, Grossman L, Mouhieddine TH, Kurowski A, et al. Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T-cell therapy. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMc2504588.","DOI":"10.1056\/NEJMc2504588"},{"key":"2933_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7522","volume":"43","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Parrondo RD, Chhabra S, Dooley K, De Menezes Silva Corraes A, Gertz MA, et al. Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (PTS) receiving cilta-cel. J Clin Oncol. 2025;43. 7522.","journal-title":"J Clin Oncol"},{"key":"2933_CR60","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ, Rejeski K, Johnson PC, Raje N, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood. 2023;142:1243\u201348.","journal-title":"Blood"},{"key":"2933_CR61","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee W-H, Wiggin HR, Supper VM, Leick MB, Birocchi F, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood. 2023;142:1248\u201352.","journal-title":"Blood"},{"key":"2933_CR62","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Puliafito BR, Graham CE, Leick MB, Chowdhury MdR, King M, et al. Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood. 2025;145:2788\u201393.","journal-title":"Blood"},{"key":"2933_CR63","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","volume":"9","author":"K Kelly","year":"2025","unstructured":"Kelly K, Cooperrider JH, Bishop MR, Kosuri S, Jakubowiak A, Derman BA. Intrathecal chemotherapy for ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity. Blood Adv. 2025;9:3613\u20136.","journal-title":"Blood Adv"},{"key":"2933_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.14740\/jh2046","volume":"14","author":"B Wirk","year":"2025","unstructured":"Wirk B, Lim J. Ruxolitinib is an effective therapy for ciltacabtagene autoleucel-associated parkinsonism in multiple myeloma. J Hematol. 2025;14:146\u201351.","journal-title":"J Hematol"},{"key":"2933_CR65","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2025-2392","volume":"146","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, et al. Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma. Blood. 2025;146:2392.","journal-title":"Blood"},{"key":"2933_CR66","doi-asserted-by":"publisher","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","volume":"10","author":"K Baur","year":"2022","unstructured":"Baur K, Heim D, Beerlage A, Poerings AS, Kopp B, Medinger M, et al. Dasatinib for treatment of CAR T-cell therapy-related complications. J Immunother Cancer. 2022;10:e005956.","journal-title":"J Immunother Cancer"},{"key":"2933_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019;11:eaau5907.","journal-title":"Sci Transl Med"},{"key":"2933_CR68","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3:711\u20137.","journal-title":"Blood Adv"},{"key":"2933_CR69","doi-asserted-by":"publisher","first-page":"S872","DOI":"10.14309\/01.ajg.0001143756.10701.d1","volume":"120","author":"R Trieu","year":"2025","unstructured":"Trieu R, Singh A, Kapur S. S4074 chimeric antigen receptor T-cell therapy induced enterocolitis and treatment with vedolizumab. J Am Coll Gastroenterol ACG. 2025;120:S872.","journal-title":"J Am Coll Gastroenterol ACG"},{"key":"2933_CR70","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","volume":"9","author":"A Bajwa","year":"2025","unstructured":"Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, et al. Siltuximab for chimeric antigen receptor T-cell therapy\u2013related CRS and ICANS: a multicenter retrospective analysis. Blood Adv. 2025;9:170\u20137.","journal-title":"Blood Adv"},{"key":"2933_CR71","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382:1811\u201322.","journal-title":"N Engl J Med"},{"key":"2933_CR72","first-page":"S239","volume":"31","author":"WT Johnson","year":"2025","unstructured":"Johnson WT, Brumwell N, Ganesan N, Perica K, Kabel C, Oved JH, et al. Emapalumab for the treatment of toxicities associated with CD19 CAR-T cells in adult patients. Transpl Cell Ther. 2025;31:S239\u201340.","journal-title":"Transpl Cell Ther"},{"key":"2933_CR73","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"Ludwig","year":"2023","unstructured":"Ludwig, Terpos H, Donk E, van de N, Mateos M-V, Moreau P, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24:e255\u2013e269.","journal-title":"Lancet Oncol"},{"key":"2933_CR74","doi-asserted-by":"publisher","unstructured":"Dhakal B, Iida S, Sidiqi MH, Zamagni E, Yoon S-S, Callander N, et al. Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma | Blood | American Society of Hematology. https:\/\/doi.org\/10.1182\/blood-2025-2215.","DOI":"10.1182\/blood-2025-2215"},{"key":"2933_CR75","first-page":"S215","volume":"31","author":"J Turner","year":"2025","unstructured":"Turner J, Forsberg PA, Nicholson S, Schade H, Matous J, Gregory TK. Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma. Transpl Cell Ther Publ Am Soc Transpl Cell Ther. 2025;31:S215\u20136.","journal-title":"Transpl Cell Ther Publ Am Soc Transpl Cell Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02933-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:13:58Z","timestamp":1778109238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02933-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2933"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02933-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. is supported by research grants from the Jose Carreras Leukemia Foundation, the International Myeloma Society and the Hector Foundation as well as European Union project CERTAINTY. MM is on advisory boards, and receives honoraria and research support for\/from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, SpringWorks, Sanofi, Takeda. S.Z.U. Grants and personal fees: AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Merck, Mundipharma, Oncopeptides, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda. S.M. Consultancy: Evicore, Optum, BioAscend, Janssen Oncology, BMS, AbbVie, HMP Education, and Legend Biotech; Honoraria: OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications. Research funding: Janssen Oncology, BMS, Allogene Therapeutics, Fate Therapeutics, Caribou Therapeutics, and Takeda Oncology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}